e-Article
EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss
Document Type
Abstract
Author
Source
In Value in Health June 2024 27(6) Supplement:S131-S132
Subject
Language
ISSN
1098-3015